Wolfgang Miesbach: ISTH 2026 Marks a New Era in Immune Thrombocytopenia Management
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”ISTH 2026 is going to be really interesting for ITP
Across several oral presentations in the Platelet Disorders / ITP, HIT, PF4 Antibodies session (OC 25.1–25.5), we see how the field is shifting toward faster, more durable responses, better patient‑reported outcomes, and careful safety profiling:
First‑line innovation
OC 25.1 – RODEX study (M.-E. Mingot‑Castellano et al.): A large multicenter phase 3 trial comparing dexamethasone alone vs dexamethasone plus romiplostim as first‑line treatment in newly diagnosed ITP shows higher sustained response off treatment with the combination (ROMDEX), while maintaining fatigue, quality of life and healthcare resource use.
Rapid and durable platelet responses
- OC 25.2 – ADVANCE IV (Y. Miyakawa, C. Broome, M. Carpenedo, B. González Sánchez and colleagues): IV efgartigimod, an Fc‑engineered IgG1 fragment, demonstrates rapid platelet count increases as early as day 7, with a significantly higher proportion of patients achieving sustained responses versus placebo in the phase 3 trial and its open‑label extension.
- OC 25.5 – VAYHIT2 (F. Zaja, H. Al‑Samkari, N. Cooper and co‑authors): Ianalumab (anti‑BAFF) added to eltrombopag in second‑line primary ITP leads to rapid, robust and durable platelet responses, enabling tapering and discontinuation of the TPO‑RA in many patients and pointing toward immune‑modulating combinations rather than lifelong stimulation alone.
Safety and long‑term risk
OC 25.3 – LUNA 2/3 integrated analysis (D. Kuter, N. Cooper, Y. Miyakawa, W. Ghanima and colleagues): Rilzabrutinib, a highly selective BTK inhibitor, shows low rates of cardiovascular adverse events and no apparent increase versus placebo despite longer exposure, an important safety signal in adults with persistent/chronic ITP, who already carry elevated thromboembolic risk.
Patient‑reported outcomes and HRQoL
- OC 25.4 – Mezagitamab phase 2 (S. Wang et al.): The anti‑CD38 antibody mezagitamab in chronic/persistent ITP is associated with early and clinically meaningful improvements across multiple ITP‑PAQ domains (symptoms, physical fatigue, social activities, psychological health, overall QoL), with sustained benefits even after treatment cessation.
- Together, these ISTH oral abstracts illustrate how future ITP care will balance efficacy, tolerability, comorbidity risk and patient‑reported outcomes—moving from ‘platelet counts only’ toward mechanism‑based, patient‑focused therapy.”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series